
Proceedings Paper
Photodynamic inactivation of enveloped viruses using sapphyrin, a 22 pi-electron expanded porphyrin: possible approaches to prophylactic blood purification protocolsFormat | Member Price | Non-Member Price |
---|---|---|
$17.00 | $21.00 |
Paper Abstract
The in vitro photodynamic inactivation ofherpes simplex virus (HSV-1), an enveloped virus with
a membranous coat, was studied using the decaalky sapphyrin 2. This new sensitizer, an unusual 22 icelectron
"expanded porphyrin" with an absorption maximum at roughly 680 nm, generates singlet oxygen
in roughly 25% quantum yield in its non-aggregated monomeric form and is very efficient for the
photo-inactivation of HSV- 1 . It is as active as dihematoporphyrin derivative (DHE) on a per macrocycle
basis and, because of light absorption by oxyhemoglobin, considerably more so in blood on a per mcident
light intensity basis. Supporting fluorescence studies indicate that compound 2 has a high affinity
for nonpolar environments, where it exists in its most active monomeric form, suggesting a mechanism
of action that depends both on selective localization in the HSV- 1 viral membrane and accompanying
efficient singlet oxygen production. In preliminary experiments with cell-free HIV-1 (also an enveloped
virus), it was found that compound 2 effects a ca. 50% photo-killing with little dark toxicity at 4 jiM concentration
and an essentially complete photo-eradication at 16 jiM concentration, as judged by standard
reverse transcriptase assay. At this latter concentration, however, the light-induced viral inactivation is
accompanied by considerable dark toxicity, which, on the basis of control experiments with uninfected
cells, is ascribed to a high sensitivity of the H9 cell line employed and not to an overall, or inherent, cytotoxicity
of the sapphyrin nucleus.
Paper Details
Date Published: 1 July 1990
PDF: 13 pages
Proc. SPIE 1203, Photodynamic Therapy: Mechanisms II, (1 July 1990); doi: 10.1117/12.17669
Published in SPIE Proceedings Vol. 1203:
Photodynamic Therapy: Mechanisms II
Thomas J. Dougherty, Editor(s)
PDF: 13 pages
Proc. SPIE 1203, Photodynamic Therapy: Mechanisms II, (1 July 1990); doi: 10.1117/12.17669
Show Author Affiliations
Jonathan L. Sessler, Univ. of Texas/Austin (United States)
Michael J. Cyr, Univ. of Texas/Austin (United States)
Bhaskar G. Maiya, Univ. of Texas/Austin (United States)
Millard M. Judy, Baylor Univ. Medical Ctr. (United States)
Joseph T. Newman, Baylor Univ. Medical Ctr. (United States)
Michael J. Cyr, Univ. of Texas/Austin (United States)
Bhaskar G. Maiya, Univ. of Texas/Austin (United States)
Millard M. Judy, Baylor Univ. Medical Ctr. (United States)
Joseph T. Newman, Baylor Univ. Medical Ctr. (United States)
Helen L. Skiles, Baylor Univ. Medical Ctr. (United States)
Richard L. Boriak, Baylor Univ. Medical Ctr. (United States)
James Lester Matthews, Baylor Univ. Medical Ctr. (United States)
Tran C. Chanh, Southwest Foundation for Biomedical Research (United States)
Richard L. Boriak, Baylor Univ. Medical Ctr. (United States)
James Lester Matthews, Baylor Univ. Medical Ctr. (United States)
Tran C. Chanh, Southwest Foundation for Biomedical Research (United States)
Published in SPIE Proceedings Vol. 1203:
Photodynamic Therapy: Mechanisms II
Thomas J. Dougherty, Editor(s)
© SPIE. Terms of Use
